Literature DB >> 28590590

Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.

Maria Dichiara1, Agostino Marrazzo1, Orazio Prezzavento1, Simona Collina2, Antonio Rescifina1, Emanuele Amata1.   

Abstract

Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis belong to a group of infectious diseases known as neglected tropical diseases and are induced by infection with protozoan parasites named trypanosomatids. Drugs in current use have several limitations, and therefore new candidate drugs are required. The majority of current therapeutic trypanosomatid targets are enzymes or cell-surface receptors. Among these, eukaryotic protein kinases are a major group of protein targets whose modulation may be beneficial for the treatment of neglected tropical protozoan diseases. This review summarizes the finding of new hit compounds for neglected tropical protozoan diseases, by repurposing known human kinase inhibitors on trypanosomatids. Kinase inhibitors are grouped by human kinase family and discussed according to the screening (target-based or phenotypic) reported for these compounds on trypanosomatids. This collection aims to provide insight into repurposed human kinase inhibitors and their importance in the development of new chemical entities with potential beneficial effects on the diseases caused by trypanosomatids.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug discovery; kinase inhibitors; neglected tropical diseases; parasites; repurposing

Mesh:

Substances:

Year:  2017        PMID: 28590590     DOI: 10.1002/cmdc.201700259

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  4 in total

1.  Repositioning Salirasib as a new antimalarial agent.

Authors:  Exequiel O J Porta; Ignasi Bofill Verdaguer; Consuelo Perez; Claudia Banchio; Mauro Ferreira de Azevedo; Alejandro M Katzin; Guillermo R Labadie
Journal:  Medchemcomm       Date:  2019-06-21       Impact factor: 3.597

2.  Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3.

Authors:  Victor Sebastián-Pérez; Paula Martínez de Iturrate; Montserrat Nácher-Vázquez; Luis Nóvoa; Concepción Pérez; Nuria E Campillo; Carmen Gil; Luis Rivas
Journal:  Biomedicines       Date:  2022-05-14

3.  FINDSITEcomb2.0: A New Approach for Virtual Ligand Screening of Proteins and Virtual Target Screening of Biomolecules.

Authors:  Hongyi Zhou; Hongnan Cao; Jeffrey Skolnick
Journal:  J Chem Inf Model       Date:  2018-10-16       Impact factor: 4.956

4.  Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

Authors:  Michael G Thomas; Manu De Rycker; Myriam Ajakane; Sébastian Albrecht; Ana Isabel Álvarez-Pedraglio; Markus Boesche; Stephen Brand; Lorna Campbell; Juan Cantizani-Perez; Laura A T Cleghorn; Royston C B Copley; Sabrinia D Crouch; Alain Daugan; Gerard Drewes; Santiago Ferrer; Sonja Ghidelli-Disse; Silvia Gonzalez; Stephanie L Gresham; Alan P Hill; Sean J Hindley; Rhiannon M Lowe; Claire J MacKenzie; Lorna MacLean; Sujatha Manthri; Franck Martin; Juan Miguel-Siles; Van Loc Nguyen; Suzanne Norval; Maria Osuna-Cabello; Andrew Woodland; Stephen Patterson; Imanol Pena; Maria Teresa Quesada-Campos; Iain H Reid; Charlotte Revill; Jennifer Riley; Jose Ramon Ruiz-Gomez; Yoko Shishikura; Frederick R C Simeons; Alasdair Smith; Victoria C Smith; Daniel Spinks; Laste Stojanovski; John Thomas; Stephen Thompson; Tim Underwood; David W Gray; Jose M Fiandor; Ian H Gilbert; Paul G Wyatt; Kevin D Read; Timothy J Miles
Journal:  J Med Chem       Date:  2018-12-20       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.